Swiss Re has created a dedicated Head of Transactions role for its Life and Health Reinsurance division, naming Dean Galligan—a former Goldman Sachs and Phoenix Group executive with over 25 years in structured finance and life insurance—to lead the function effective August 1, 2026. The appointment signals Swiss Re’s intent to compete aggressively in the accelerating wave of longevity swaps, legacy book acquisitions, and complex capital solutions building across developed insurance and pension markets.
Who is Dean Galligan and Why the Hire Signals Intent
Galligan joins Swiss Re from Phoenix Group, the London-listed life and savings firm with over £260 billion in assets under management, where he served as Chief Capital Officer from 2023 to 2026—directly responsible for the balance sheet optimization and capital transactions strategy of one of the UK’s largest closed life book consolidators. Before Phoenix Group, he spent more than a decade at Goldman Sachs as European Head of Pensions and Insurance Structuring, and held senior roles at Barclays as Global Head of Cross-Asset Structuring. His career sits precisely at the intersection of institutional capital markets, life insurance balance sheet management, and structured finance—the skill profile required to design and execute hybrid instruments combining reinsurance with securitization or private placement. According to Reinsurance News, Galligan’s appointment unifies Swiss Re’s global L&H transaction teams under a single senior leader, replacing a distributed regional structure. The creation of a named global function—rather than distributing deal responsibilities across P&L centres—signals Swiss Re intends to centralize origination, accelerate time-to-close, and establish a clearer competitive identity against Hannover Re and RGA in the growing capital solutions segment of life reinsurance.
The $2 Billion Athene Deal and the US Longevity Market Entry
Swiss Re’s L&H transactions ambition is already demonstrably active. In March 2026, the reinsurer closed a $2 billion longevity reinsurance transaction with Athene, Apollo Global Management’s insurance platform—marking Swiss Re’s first significant entry into the US longevity market. The deal transfers the risk that Athene’s annuitant pool lives longer than actuarial projections from Athene’s balance sheet to Swiss Re’s risk portfolio, priced against Swiss Re’s proprietary mortality and longevity models. Swiss Re has now completed more than 30 longevity transactions globally, covering over $50 billion in pension benefits and more than one million retirees across the UK, Netherlands, Singapore, and Australia. Longevity represents approximately 17% of L&H Re insurance revenue in 2025, and the division’s net income target for 2026 is $1.7 billion according to CEO Paul Murray’s Q1 guidance. The US defined-benefit pension de-risking market is estimated at over $600 billion in liabilities seeking transfer—dwarfing the UK market, which has itself been the primary growth engine for longevity reinsurance since 2015. Galligan’s August start positions Swiss Re to pursue a material portion of this pipeline during the second half of 2026.
Why L&H Transactions Are a Growth Engine in 2026
Three structural forces are converging to make complex L&H transactions one of the highest-growth segments in global reinsurance. First, the interest rate environment of 2022–2024 significantly improved the economics of defined-benefit pension de-risking in both the UK and US, making bulk annuity and longevity swap pricing more attractive to plan sponsors than at any point since 2008. Second, Solvency II and its international equivalents create capital incentives for life carriers to transfer longevity risk off-balance-sheet, particularly as regulators scrutinize internal model assumptions for long-duration liabilities under upcoming IFRS 17 reviews. Third, the demographic cohort of retiring baby boomers across North America and Europe is expanding the universe of pension assets seeking de-risking solutions at a pace that outstrips the current capacity of specialist providers. The growth dynamic in reinsurance is not limited to life lines: as we noted in our coverage of Saudi Re’s Q1 2026 results driven by mandatory cession rules, regulatory-driven risk transfer mandates are reshaping reinsurance economics globally—including in markets that have historically been net exporters of risk rather than capital solutions buyers.. For context, see Swiss Re’s Q1 2026 net income of USD 1.5 billion.
Implications for Life Carriers, Pension Sponsors, and Advisers
For life insurance carriers managing closed legacy books—particularly in the UK, Germany, Netherlands, and increasingly the US—Swiss Re’s dedicated transactions function lowers friction in accessing longevity reinsurance and structured capital solutions. Galligan’s capital markets background positions him to design instruments that may combine treaty reinsurance with private placement or sidecar structures, potentially broadening the investor base beyond traditional balance-sheet reinsurers and reducing pricing spreads for large transactions. For pension trustees and corporate plan sponsors evaluating bulk annuity buy-ins or longevity swaps, the entry of additional well-capitalized capacity into the longevity transfer market creates competitive tension that may tighten pricing in 2026–2027. Hannover Re and RGA, both dominant volume players in the UK pension risk transfer market, face pressure to match Swiss Re’s execution velocity or differentiate on structuring capability. For transaction advisers—investment banks, actuarial consultants, and specialist brokers—centralization of Swiss Re’s dealflow under a single senior executive means a clearer relationship contact for complex originations. The consolidation of MGAs and specialty underwriters we have been tracking—such as Markel’s discipline under MGA-led rate pressure in casualty—reflects the same broader trend: specialist capital is increasingly organized around dedicated functions with deep product expertise rather than generalist underwriting platforms.
